Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Current Oncology Reports · 2024-06 · 26 (6) · 679-690
DOI: 10.1007/s11912-024-01537-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, online erschienen am 27.04.2024. Verfasst von Mina Meseha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Purpose of Review Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role of Minimal Residual Disease (MRD) assessment in facilitating response-adapted therapeutic decision making to individualize therapy in MM. Recent Findings MRD has been repeatedly demonstrated to provide strong prognostic information, superseding traditional IMWG response criteria. The use of MRD to modulate therapy remains controversial. Here, we review the existing landscape of MRD-adapted trial designs in both induction/consolidation and maintenance settings, including recent data from influential studies and retrospective analyses. We navigate existing data, leverage the increased resolution of longitudinal MRD assessments, and comment on trials in progress to explain our current utilization of MRD in the clinic. Summary MRD transcends traditional response assessments by providing a window into disease-treatment interaction over time. As a strong patient-level surrogate, MRD has limited current use in individualizing treatment, but is poised to comprehensively shape treatment strategies at many key points in a patient’s MM course.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA.
- Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA. bxd500@med.miami.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Meseha, M., Hoffman, J., Kazandjian, D., Landgren, O., & Diamond, B. (2024). Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions. Current Oncology Reports, 26(6), 679-690. https://doi.org/10.1007/s11912-024-01537-2
Vancouver
Meseha M, Hoffman J, Kazandjian D, Landgren O, Diamond B. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions. Current Oncology Reports. 2024;26(6):679-690. doi:10.1007/s11912-024-01537-2
BibTeX
@article{Meseha2024,
author = {Meseha, Mina and Hoffman, James and Kazandjian, Dickran and Landgren, Ola and Diamond, Benjamin},
title = {Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions},
journal = {Current Oncology Reports},
year = {2024},
volume = {26},
number = {6},
pages = {679--690},
doi = {10.1007/s11912-024-01537-2}
}
EUVIMED